{"id":340,"date":"2023-01-13T10:23:39","date_gmt":"2023-01-13T08:23:39","guid":{"rendered":"https:\/\/bcamonitor.org\/?p=340"},"modified":"2026-09-22T13:32:21","modified_gmt":"2026-09-22T13:32:21","slug":"alternating-cystoscopy-with-a-urinary-marker-for-the-surveillance-of-intermediate-risk-nmibc","status":"publish","type":"post","link":"https:\/\/bcamonitor.org\/?p=340","title":{"rendered":"Alternating cystoscopy with a urinary marker for the surveillance of intermediate-risk NMIBC"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px|||||&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; min_height=&#8221;446px&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; header_text_color=&#8221;#3b8dbf&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<p>Watch the <strong>clinical case discussion<\/strong> by <strong>Prof. Dr. Paolo Gontero<\/strong> to learn more about the advantages of alternating cystoscopy with a urinary marker for the surveillance of intermediate-risk non-muscle-invasive bladder cancer (NMIBC).<\/p>\n<p>Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy.<\/p>\n<p>He presents 2 clinical patient cases with intermediate-risk NMIBC (Bruce and Jonathan) for whom the use of a urinary biomarker could be safely implemented in the follow-up scheme to detect recurrences.<\/p>\n<p>[\/et_pb_text][et_pb_video src=&#8221;https:\/\/youtu.be\/5ad_mrR0EV4&#8243; thumbnail_overlay_color=&#8221;rgba(0,0,0,0.6)&#8221; _builder_version=&#8221;4.16&#8243; width=&#8221;70%&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_video][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_button button_url=&#8221;https:\/\/bcamonitor.org\/slides-brochure\/&#8221; button_text=&#8221;Download the free slide resource and brochure&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.16&#8243; custom_button=&#8221;on&#8221; button_text_color=&#8221;#ffffff&#8221; button_bg_color=&#8221;#3b8dbf&#8221; button_border_width=&#8221;0px&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.8.2&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;2px||5px|||&#8221; global_module=&#8221;303&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Watch the clinical case discussion by Prof. Dr. Paolo Gontero to learn more about the advantages of alternating cystoscopy with a urinary marker for the surveillance of intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":222,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinicalcase"],"_links":{"self":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=340"}],"version-history":[{"count":1,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/340\/revisions"}],"predecessor-version":[{"id":371,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/340\/revisions\/371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/media\/222"}],"wp:attachment":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}